GET DAILY SIGNALSWhy Is Trulieve Cannabis (TRLV) Stock Up +1.56% Today?
Key Takeaways
- TRLV shares rose +1.56% on Thursday, rebounding to $11.07 from a prior-session close of $10.90.
- The gain follows a sharp post-earnings selloff, as investors reassessed the company's strong third-quarter results released a day earlier.
- Primary catalyst: Follow-through buying after Q3 revenue of $230 million, 64% gross margin, and adjusted EBITDA of $89 million.
- Secondary drivers: Final DEA registrations under federal Schedule III rescheduling and the repayment of a $65 million mortgage.
- Broader cannabis-sector sentiment and the stock's re-testing of key technical support are also shaping intraday trading.
- Traders are watching for sustained volume, technical levels near the 50-day moving average, and any fresh regulatory or guidance updates.
- You can find detailed Price Targets, Earnings history, and Forecast data for TRLV on additional Tickeron pages.
- Explore Trending AI Robots to see which automated trading strategies are performing best in current market conditions.
Opening Summary
TRLV — Trulieve Cannabis Corp., a vertically integrated U.S. medical cannabis multi-state operator with retail, cultivation, and processing operations across Florida, Georgia, Pennsylvania, and West Virginia — traded higher on Thursday, adding 1.56% to $11.07. The advance, equal to about $0.17 per share, lifted the stock from its prior close of $10.90 and marked a modest recovery after shares slid roughly 6% the day before in the immediate reaction to third-quarter earnings. Markets attributed the rebound to bargain-hunting and renewed focus on the company's improving profitability, cash generation, and its newly finalized federal regulatory standing.
Post-Earnings Reassessment
The session's move is best understood as a re-evaluation of results Trulieve released on November 5. For the third quarter, the company reported revenue of $230 million, up 4% year over year and sequentially, a gross margin of 64%, and adjusted EBITDA of $89 million (a 39% margin). Operating cash flow reached $74 million, contributing to a quarter-end cash balance of about $327 million. Adjusted earnings per share of $0.09 came in ahead of consensus expectations. Despite the solid operational print, shares sold off initially amid cautious fourth-quarter guidance — management projected only low-single-digit revenue growth and flagged expected holiday promotional pressure and non-cash accounting items — before finding buyers in the following session.
Regulatory Tailwinds and Balance-Sheet Strength
Beyond the quarterly numbers, investors are weighing structural catalysts. Following the federal rescheduling of state-licensed medical cannabis to Schedule III, Trulieve received final DEA registrations for its medical dispensaries and production facilities, positioning the company as a federally lawful Schedule III operator. Management has highlighted that rescheduling removes the punitive Section 280E tax burden going forward and expands access to institutional investors and strategic partners. Separately, the company said it fully repaid a $65 million mortgage on its Jefferson County, Florida cultivation campus ahead of maturity, a step expected to reduce annual interest expense and improve profitability and cash flow.
Market Context and Trading Activity
Thursday's uptick unfolded against a backdrop of ongoing enthusiasm around cannabis-policy reform, with management citing the midterm elections as keeping cannabis legislation a central theme heading into 2027. The company is also seeing accelerating growth in Georgia, where patient enrollment has surpassed 60,000 and traffic and units sold rose roughly sevenfold, while Texas represents a larger long-term opportunity pending final licensure. From a technical standpoint, TRLV continues to trade below its 50-day moving average near $11.20 after the prior day's pullback, with the rebound reflecting a stabilization rather than a decisive breakout. Trading volumes have remained active relative to the stock's typical daily average as investors reposition following the earnings release.
What Comes Next for TRLV
Looking ahead, traders will monitor Trulieve's fourth-quarter execution against its low-single-digit revenue-growth guidance, the holiday-driven promotional environment, and gross-margin trends. Regulatory developments — including potential broader rescheduling, updated Treasury guidance on tax treatment, and progress on measures such as SAFE Banking — remain key swing factors. Georgia dispensary expansion, wholesale distribution to independent pharmacies, and the conversion of the company's conditional Texas license are additional catalysts. Risks include an unresolved tax position covering 2019 onward, execution challenges in newly opening markets, and the inherent volatility of a still-developing federal regulatory framework for cannabis.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies that are performing strongest under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. If you're interested in data-driven trading signals, explore the Trending AI Robots section to see which bots are leading the field today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRLV in +4.50% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TRLV advanced for three days, in 188 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TRLV just turned positive on October 22, 2026. Looking at past instances where TRLV's MACD turned positive, the stock continued to rise in 22 of 33 cases over the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 49 cases where TRLV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRLV as a result. In 82 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
TRLV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
TRLV broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TRLV entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.735) is normal, around the industry mean (7.445). P/E Ratio (-4.413) is within average values for comparable stocks, (0.293). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement